GRg3对直肠癌放疗患者肠道菌群影响的研究进展  

Research Progress of Effects of GRg3 on Intestinal Flora in Patients with Radiotherapy for Rectal Cancer

作　　者：付亚雯 蔡宏懿[2] 

机构地区：[1]甘肃中医药大学第一临床医学院,甘肃 兰州 [2]甘肃省人民医院放疗科,甘肃 兰州

出　　处：《临床医学进展》2024年第12期214-219,共6页Advances in Clinical Medicine

摘　　要：直肠癌发病率逐年递增,由于早期筛查的普及率低,中老年人规律接受肠镜随访的比例低,大多数结直肠癌患者因出现典型症状而就诊时肿瘤已处于进展期。放疗是局部晚期直肠癌患者治疗中至关重要的一部分,腹盆腔肿瘤患者放疗后会有不同程度的放射性肠损伤,合并肠道菌群紊乱。传统药物治疗效果不佳,且在免疫治疗方向大多是微卫星稳定(MSS),对基于抗PD-1的免疫治疗没有反应,迫切需要新的治疗方案。人参皂苷Rg3 (Ginsenoside Rg3, GRg3)是从人参中提取的活性单体,具有抗炎、抗肿瘤、抗血管生成及增强免疫功能等作用。了解GRg3与肠道菌群及其代谢产物之间的关系以调节肠道微生态,可能增强直肠癌免疫治疗敏感性,为直肠癌免疫治疗寻找新的突破口。本文分别从GRg3、肠道菌群以及肿瘤免疫功能三者之间关系进行综述。The incidence of rectal cancer is increasing year by year. Due to the low penetration rate of early screening and the low proportion of middle-aged and elderly people regularly receiving colonoscopy follow-up, most patients with colorectal cancer have advanced tumors when they see a doctor due to typical symptoms. Radiotherapy is a crucial part of the treatment of patients with locally advanced rectal cancer. After radiotherapy, patients with abdominal and pelvic tumors will have different degrees of radioactive intestinal damage combined with intestinal flora disorder. Traditional drug therapy is not effective, and most of them are microsatellite stabilized (MSS) in the direction of immunotherapy, which does not respond to anti-PD-1-based immunotherapy, so a new treatment plan is urgently needed. Ginsenoside Rg3 (GRg3) is an active monomer extracted from ginseng, which has anti-inflammatory, anti-tumor, anti-angiogenesis and immune function enhancement effects. Understanding the relationship between GRg3 and intestinal flora and its metabolites in order to regulate intestinal microeco

关 键 词：人参皂苷RG3 肠道菌群失调 免疫功能 

分 类 号：R73[医药卫生—肿瘤]